PIK3CA-related overgrowth: silver bullets from the cancer arsenal?

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrum

(2022) Gemma Garreta Fontelles et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib

(2022) Gabriel Morin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation

(2022) Bart Vanhaesebroeck et al.   Cancer Discovery

Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel–Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study

(2021) M. Luu et al.   GENETICS IN MEDICINE

Defining key design elements of registry-based randomised controlled trials: a scoping review

(2020) Bill Karanatsios et al.   Trials

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum

(2018) Victoria E. R. Parker et al.   GENETICS IN MEDICINE

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

(2018) Quitterie Venot et al.   NATURE

Cancer-Associated PIK3CA Mutations in Overgrowth Disorders

(2018) Ralitsa R. Madsen et al.   TRENDS IN MOLECULAR MEDICINE